Creative Bioarray Releases IPSC-Derived Cells to Support Human Disease Research
Creative Bioarray announced the release of its iPSC-derived cells to support human disease research.
USA – January 30, 2023 /MarketersMEDIA/ —
Creative Bioarray is a cell biology and cell technology company dedicated to providing innovative pre-clinical drug discovery solutions with a focus on disease-relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate the pace of drug discovery. With a network of collaborators and partners across biotech and pharma, Creative Bioarray continues to make discoveries and expand our product offerings to maintain our position as a leader in the marketplace. Recently, Creative Bioarray announced the release of its iPSC-derived cells to support human disease research.
The emergence of stem cell technology has provided new tools for drug screening, target identification, and toxicity testing, thereby opening up new opportunities for drug discovery and development. The discovery of reprogramming patient-derived somatic cells into iPSCs offers a promising alternative for generating many human cell types, but rarely at the scale, consistency, and cost points required for HTS.
The widespread use of hiPSC-derived mature cell types has been limited by complex and suboptimal differentiation protocols. These limitations have been largely overcome by applying a method of cellular reprogramming enabled by the uniquely designed gene switch opti-ox (optimization-induced overexpression) technology.
This proprietary technology overcomes gene silencing and enables controlled expression of transcription factors, leading to definitive reprogramming of hiPSC cultures. Opti-ox technology enables large-scale generation of highly consistent and functional cells from hiPSCs, including those carrying disease-specific mutations, providing high-quality human models to improve research outcomes and drug discovery efficiency.
Opti-ox cell reprogramming provides access to the highest quality cell models using a simple protocol. Homogenous, mature hiPSC-derived functional cells can be produced within days, significantly reducing the time and resources required to generate mature cell types.
iPSC-derived human cells provide customers with:
Consistency: Batch-to-batch reproducibility and homogeneity create robust human models for research and high-throughput.
Speed: Ready to experiment within days of revival.
Scalability: Industrial-scale quantities allow cells to be used in a range of applications from research to screening purposes.
Ease of use: Cells arrive programmed to mature rapidly after thawing, requiring only one medium in a two-step protocol.
“We are committed to providing you with fully characterized iPSC-derived cells to satisfy your specific research needs.” said Hannah Cole, the marketing director of Creative Bioaray, she also added, “Our team will roll out more cell types to support your research needs.”
About Creative Bioarray
Creative Bioarray is dedicated to offering customers innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house expert support, Creative Bioarray has already countenanced research all around the world.
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: +1 6313868241
Release ID: 89089258
If you detect any issues, problems, or errors in this press release content, kindly contact firstname.lastname@example.org to notify us. We will respond and rectify the situation in the next 8 hours.